BibTex format
@article{Feleszko:2026:10.1016/j.anai.2025.09.015,
author = {Feleszko, W and Caminati, M and Gern, JE and Johnston, SL and Marchese, C and Clarke, D and Ambrose, CS and Lindsley, AW},
doi = {10.1016/j.anai.2025.09.015},
journal = {Ann Allergy Asthma Immunol},
pages = {61--65.e1},
title = {Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses.},
url = {http://dx.doi.org/10.1016/j.anai.2025.09.015},
volume = {136},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin. In the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies, tezepelumab reduced exacerbations and improved lung function, asthma control, and health-related quality of life vs placebo in patients with severe, uncontrolled asthma. OBJECTIVE: To evaluate the incidence of asthma exacerbations co-occurring with documented acute respiratory illnesses attributed to infections. METHODS: Patients were randomized 1:1 to receive tezepelumab 210 mg subcutaneously or placebo every 4 weeks for 52 weeks. The incidence of asthma exacerbations co-occurring with respiratory illness-related adverse events (AEs) was assessed. Co-occurrence was defined as at least 1 day of overlap between a respiratory illness-related AE and the asthma exacerbation period beginning 7 days before the start of the exacerbation until the end of the asthma exacerbation. RESULTS: Of the 1334 patients (tezepelumab, n = 665; placebo, n = 669) included, 312 experienced at least 1 asthma exacerbation co-occurring with a respiratory illness-related AE attributed to an infection. The incidence of asthma exacerbation co-occurring with a respiratory illness-related AE was lower in the tezepelumab group than in the placebo group overall (18.2% vs 28.6%; exposure-adjusted incidence difference [EAID], -11.1 [95% CI: -15.75, -6.41]) and among patients with perennial allergy (EAID, -11.6 [95% CI: -17.44, -5.69]) and without perennial allergy (EAID, -10.2 [95% CI: -18.16, -2.10]). CONCLUSION: Tezepelumab reduced asthma exacerbations attributed to respiratory infections in patients with severe, uncontrolled asthma compared with placebo, irrespective of perennial allergy status. TRIAL REGISTRATION: This is a pooled analysis of 2 studies registered at Clinicaltrials.gov: PATHWAY (NCT02054130) and NAVIGATOR (NCT03347279).
AU - Feleszko,W
AU - Caminati,M
AU - Gern,JE
AU - Johnston,SL
AU - Marchese,C
AU - Clarke,D
AU - Ambrose,CS
AU - Lindsley,AW
DO - 10.1016/j.anai.2025.09.015
EP - 65
PY - 2026///
SP - 61
TI - Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses.
T2 - Ann Allergy Asthma Immunol
UR - http://dx.doi.org/10.1016/j.anai.2025.09.015
UR - https://www.ncbi.nlm.nih.gov/pubmed/41072729
VL - 136
ER -